Semglee is both biosimilar to and interchangeable with Lantus, and is the first interchangeable biosimilar approved by the Food and Drug Administration.
Spiriva Handihaler had a market value of $1.5 billion for the 12 months ended May 2021, although actual generic market values are expected to be lower.